Table 2.
Summary of the RRs of adverse events in patients with non-small-cell lung cancer
| Adverse events | Incidence rate (comb group) | Incidence rate (mono group) | RR | 95% CI | p Value |
|---|---|---|---|---|---|
| Hypertension | 84/795 (10.57%) | 36/796 (4.52%) | 2.19 | 0.73 to 6.61 | 0.164 |
| Rash | 144/933 (15.43%) | 57/934 (6.10%) | 2.59 | 1.40 to 4.79 | 0.002 |
| Haemorrhage | 18/756 (2.38%) | 14/757 (1.85%) | 1.28 | 0.65 to 2.52 | 0.480 |
| Proteinuria | 17/505 (3.37%) | 9/505 (1.78%) | 1.84 | 0.84 to 4.00 | 0.126 |
| Diarrhoea | 60/545 (11.0%) | 20/544 (3.68%) | 2.73 | 1.12 to 6.67 | 0.027 |
| ILD-like events | 4/681 (0.59%) | 1/680 (0.15%) | 3.00 | 0.47 to 18.96 | 0.244 |
Comb, combination; ILD-like events, interstitial lung disease-like events; mono, monotherapy; RR, risk ratio.